Dose escalation studies with caspofungin against Candida glabrata

Marianna Domán, Renátó Kovács, David S. Perlin, G. Kardos, R. Gesztelyi, B. Juhász, Aliz Bozó, László Majoros

Research output: Article

6 Citations (Scopus)

Abstract

Echinocandins are recommended as first-line agents against invasive fungal infections caused by Candida glabrata, which still carry a high mortality rate. Dose escalation of echinocandins has been suggested to improve the clinical outcome against C. glabrata. To address this possibility, we performed in vitro and in vivo experiments with caspofungin against four WT C. glabrata clinical isolates, a drug-susceptible ATCC 90030 reference strain and two echinocandinresistant strains with known FKS mutations. MIC values for the clinical isolates in RPMI 1640 were ≤0.03 mg l-1 but increased to 0.125–0.25 mg l-1 in RPMI 1640+50% serum. In RPMI 1640+50% serum, the replication of C. glabrata was weaker than in RPMI 1640.Caspofungin in RPMI 1640 at 1 and 4 mg l-1 showed a fungicidal effect within 7 h against three of the four clinical isolates but was only fungistatic at 16 and 32 mg l-1 (paradoxically decreased killing activity). In RPMI 1640+50% serum, caspofungin at ≥1 mg l-1 was rapidly fungicidal (within 3.31 h) against three of the four isolates. In a profoundly neutropenic murine model, all caspofungin doses (1, 2, 3, 5 and 20 mg kg-1 daily) decreased the fungal tissue burdens significantly (P5 cells (g tissue)-1.The echinocandin-resistant strains were highly virulent in animal models and all doses were ineffective. These results confirm the clinical experience that caspofungin dose escalation does not improve efficacy.

Original languageEnglish
Pages (from-to)998-1007
Number of pages10
JournalJournal of Medical Microbiology
Volume64
Issue number9
DOIs
Publication statusPublished - szept. 1 2015

Fingerprint

caspofungin
Candida glabrata
Echinocandins
Serum
Animal Models
Mutation
Mortality

ASJC Scopus subject areas

  • Microbiology (medical)
  • Microbiology

Cite this

Dose escalation studies with caspofungin against Candida glabrata. / Domán, Marianna; Kovács, Renátó; Perlin, David S.; Kardos, G.; Gesztelyi, R.; Juhász, B.; Bozó, Aliz; Majoros, László.

In: Journal of Medical Microbiology, Vol. 64, No. 9, 01.09.2015, p. 998-1007.

Research output: Article

Domán, Marianna ; Kovács, Renátó ; Perlin, David S. ; Kardos, G. ; Gesztelyi, R. ; Juhász, B. ; Bozó, Aliz ; Majoros, László. / Dose escalation studies with caspofungin against Candida glabrata. In: Journal of Medical Microbiology. 2015 ; Vol. 64, No. 9. pp. 998-1007.
@article{a457101bece04497856f2569cb380d7e,
title = "Dose escalation studies with caspofungin against Candida glabrata",
abstract = "Echinocandins are recommended as first-line agents against invasive fungal infections caused by Candida glabrata, which still carry a high mortality rate. Dose escalation of echinocandins has been suggested to improve the clinical outcome against C. glabrata. To address this possibility, we performed in vitro and in vivo experiments with caspofungin against four WT C. glabrata clinical isolates, a drug-susceptible ATCC 90030 reference strain and two echinocandinresistant strains with known FKS mutations. MIC values for the clinical isolates in RPMI 1640 were ≤0.03 mg l-1 but increased to 0.125–0.25 mg l-1 in RPMI 1640+50{\%} serum. In RPMI 1640+50{\%} serum, the replication of C. glabrata was weaker than in RPMI 1640.Caspofungin in RPMI 1640 at 1 and 4 mg l-1 showed a fungicidal effect within 7 h against three of the four clinical isolates but was only fungistatic at 16 and 32 mg l-1 (paradoxically decreased killing activity). In RPMI 1640+50{\%} serum, caspofungin at ≥1 mg l-1 was rapidly fungicidal (within 3.31 h) against three of the four isolates. In a profoundly neutropenic murine model, all caspofungin doses (1, 2, 3, 5 and 20 mg kg-1 daily) decreased the fungal tissue burdens significantly (P5 cells (g tissue)-1.The echinocandin-resistant strains were highly virulent in animal models and all doses were ineffective. These results confirm the clinical experience that caspofungin dose escalation does not improve efficacy.",
author = "Marianna Dom{\'a}n and Ren{\'a}t{\'o} Kov{\'a}cs and Perlin, {David S.} and G. Kardos and R. Gesztelyi and B. Juh{\'a}sz and Aliz Boz{\'o} and L{\'a}szl{\'o} Majoros",
year = "2015",
month = "9",
day = "1",
doi = "10.1099/jmm.0.000116",
language = "English",
volume = "64",
pages = "998--1007",
journal = "Journal of Medical Microbiology",
issn = "0022-2615",
publisher = "Society for General Microbiology",
number = "9",

}

TY - JOUR

T1 - Dose escalation studies with caspofungin against Candida glabrata

AU - Domán, Marianna

AU - Kovács, Renátó

AU - Perlin, David S.

AU - Kardos, G.

AU - Gesztelyi, R.

AU - Juhász, B.

AU - Bozó, Aliz

AU - Majoros, László

PY - 2015/9/1

Y1 - 2015/9/1

N2 - Echinocandins are recommended as first-line agents against invasive fungal infections caused by Candida glabrata, which still carry a high mortality rate. Dose escalation of echinocandins has been suggested to improve the clinical outcome against C. glabrata. To address this possibility, we performed in vitro and in vivo experiments with caspofungin against four WT C. glabrata clinical isolates, a drug-susceptible ATCC 90030 reference strain and two echinocandinresistant strains with known FKS mutations. MIC values for the clinical isolates in RPMI 1640 were ≤0.03 mg l-1 but increased to 0.125–0.25 mg l-1 in RPMI 1640+50% serum. In RPMI 1640+50% serum, the replication of C. glabrata was weaker than in RPMI 1640.Caspofungin in RPMI 1640 at 1 and 4 mg l-1 showed a fungicidal effect within 7 h against three of the four clinical isolates but was only fungistatic at 16 and 32 mg l-1 (paradoxically decreased killing activity). In RPMI 1640+50% serum, caspofungin at ≥1 mg l-1 was rapidly fungicidal (within 3.31 h) against three of the four isolates. In a profoundly neutropenic murine model, all caspofungin doses (1, 2, 3, 5 and 20 mg kg-1 daily) decreased the fungal tissue burdens significantly (P5 cells (g tissue)-1.The echinocandin-resistant strains were highly virulent in animal models and all doses were ineffective. These results confirm the clinical experience that caspofungin dose escalation does not improve efficacy.

AB - Echinocandins are recommended as first-line agents against invasive fungal infections caused by Candida glabrata, which still carry a high mortality rate. Dose escalation of echinocandins has been suggested to improve the clinical outcome against C. glabrata. To address this possibility, we performed in vitro and in vivo experiments with caspofungin against four WT C. glabrata clinical isolates, a drug-susceptible ATCC 90030 reference strain and two echinocandinresistant strains with known FKS mutations. MIC values for the clinical isolates in RPMI 1640 were ≤0.03 mg l-1 but increased to 0.125–0.25 mg l-1 in RPMI 1640+50% serum. In RPMI 1640+50% serum, the replication of C. glabrata was weaker than in RPMI 1640.Caspofungin in RPMI 1640 at 1 and 4 mg l-1 showed a fungicidal effect within 7 h against three of the four clinical isolates but was only fungistatic at 16 and 32 mg l-1 (paradoxically decreased killing activity). In RPMI 1640+50% serum, caspofungin at ≥1 mg l-1 was rapidly fungicidal (within 3.31 h) against three of the four isolates. In a profoundly neutropenic murine model, all caspofungin doses (1, 2, 3, 5 and 20 mg kg-1 daily) decreased the fungal tissue burdens significantly (P5 cells (g tissue)-1.The echinocandin-resistant strains were highly virulent in animal models and all doses were ineffective. These results confirm the clinical experience that caspofungin dose escalation does not improve efficacy.

UR - http://www.scopus.com/inward/record.url?scp=84941555326&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941555326&partnerID=8YFLogxK

U2 - 10.1099/jmm.0.000116

DO - 10.1099/jmm.0.000116

M3 - Article

C2 - 26296340

AN - SCOPUS:84941555326

VL - 64

SP - 998

EP - 1007

JO - Journal of Medical Microbiology

JF - Journal of Medical Microbiology

SN - 0022-2615

IS - 9

ER -